SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CEPH
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: KurtVedder who wrote (67)3/15/1997 7:29:00 PM
From: harkenman   of 998
 
FACT 2: "With respect to PROVIGIL (modafinil), there are presently several products used in the United States to treat narcolepsy."
"Competition for PROVIGIL (modafinil) also is likely, because narcolepsy is currently treated with several drugs, all of which are available generically and have been available for a number of years."
"... there can be no assurance that the Company will be able to demonstrate the value of potential advantages of PROVIGIL (modafinil) to prescribing physicians and their patients."

These are statements made by Cephalon and was taken from Cephalon FORM 10-K405 Filed March 13, 1997
sec.gov

This from Cephalon itself, several treatments exist for narcolepsy, even generic. Do the research before you POST. CEPH is required by SEC regulation to disclose the truth. The stock is being hyped by stock analyst who win no matter the stock performance. See the stock tank! The facts speak for themselves!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News